Related Experiment Video
Updated: Jun 7, 2025

Delivery of the Cas9/sgRNA Ribonucleoprotein Complex in Immortalized and Primary Cells via Virus-like Particles "Nanoblades"
Published on: March 31, 2021
Enhanced CRISPR-Cas9 RNA system delivery using cell penetrating peptides-based nanoparticles for efficient in vitro
Veronica Guzman Gonzalez1, Audrey Grunenberger2, Olivier Nicoud3
1University Grenoble Alpes, INSERM U 1209, CNRS UMR 5309, Cancer Targets and Experimental Therapeutics Team, Institute for Advanced Biosciences, 38000 Grenoble, France.; DivinCell SAS, Nimes, France.
Abstract:
CRISPR-Cas9 system has emerged as a revolutionary gene-editing tool with huge therapeutic potential for addressing the underlying genetic causes of various diseases, including cancer. However, there are challenges such as the delivery method that must be overcome for its clinical application. In addition to the risk of nuclease degradation and rapid clearance of the CRISPR-Cas9 system by macrophages, the large size of Cas9, the high anionic charge density and hydrophilic nature of the RNA hinder their intracellular delivery and overall gene transfection efficiency. In this study, we engineered a novel Peptide-Based Nanoparticles ADGN for the delivery of long RNA. ADGN peptides can form stable self-assembled nanoparticles with CRISPR-Cas9 RNA. They have the ability to cross the cell membrane of various cell types, exhibiting a preference for cancer cells that overexpress laminin receptor and safeguard RNA prior their delivery into the cytoplasm. We demonstrate that ADGN peptides significantly promote CRISPR-Cas9 mediated knockout of the luciferase gene in vitro achieving 60 % efficiency with a preference for G insertion at the targeted site of luciferase gene. Moreover, we have provided evidence that these nanoparticles can also be systemically intravenously administrated in vivo in mice to deliver a functional CRISPR-Cas9 system to tumoral lung cells orthotopically implanted in the mouse, resulting in an effective gene knockout in mice. We also demonstrated that the in vivo distribution of ADGN-RNA is influenced by its peptides to RNA molar ratio. This study introduces a promising new Peptide-Based Nanoparticles for delivering CRISPR-Cas9 system in its RNA form applicable in both in vitro and in vivo models.
Insights
Novel peptide-based nanoparticles efficiently deliver CRISPR-Cas9 RNA for gene editing. These nanoparticles show promise for in vitro and in vivo applications, overcoming delivery challenges for genetic disease therapies.
Area of Science:
- Biotechnology
- Gene Therapy
- Nanomedicine
Background:
- CRISPR-Cas9 gene editing holds therapeutic promise for genetic diseases like cancer.
- Clinical application faces challenges in delivering CRISPR-Cas9 components, particularly RNA, due to degradation and poor cellular uptake.
- Existing delivery methods struggle with the size, charge, and hydrophilic nature of CRISPR-Cas9 RNA.
Purpose of the Study:
- To engineer novel peptide-based nanoparticles (ADGN) for efficient delivery of long RNA CRISPR-Cas9 systems.
- To evaluate the in vitro and in vivo efficacy and targeting capabilities of ADGN nanoparticles for gene editing.
Main Methods:
- Engineered ADGN peptides to form self-assembled nanoparticles with CRISPR-Cas9 RNA.
- Assessed nanoparticle cell membrane crossing ability and cancer cell targeting via laminin receptor.
- Evaluated CRISPR-Cas9 mediated gene knockout efficiency in vitro and in vivo following intravenous administration in mice.
Main Results:
- ADGN nanoparticles effectively delivered CRISPR-Cas9 RNA, achieving 60% gene knockout efficiency in vitro with a preference for G insertion.
- Demonstrated successful systemic intravenous administration in mice, leading to effective gene knockout in orthotopic lung tumors.
- Showed that in vivo distribution of ADGN-RNA is influenced by the peptide-to-RNA molar ratio.
Conclusions:
- ADGN peptide-based nanoparticles represent a promising new platform for delivering CRISPR-Cas9 RNA systems.
- These nanoparticles overcome key delivery barriers, enabling efficient gene editing both in vitro and in vivo.
- The study highlights the potential of ADGN for developing targeted gene therapies for genetic diseases and cancer.
Related Concept Videos
CRISPR
CRISPR and crRNAs
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...

